Search our Innovation Portfolio

Women are 50% more likely than men to be misdiagnosed or diagnosed late and 35% less likely to receive life-saving treatment. LightHearted AI has developed LightScope, a breakthrough technology that can reduce the heart valve disease (HVD) diagnosis gap.

LightScope uses laser light to captures heart sounds, ECG and Blood Pressure contactlessly in one single scan. AI algorithms analyse this data to diagnose several conditions, including HVD. LightScope is accurate (>90% accuracy for HVD), requires no training and is cost-effective, addressing underdiagnosis and late diagnosis issues.

Signatur Biosciences is developing OncoSignatur Breast (OSB), a decentralised, cost-effective breast cancer prognostic test that addresses the limitations of current centralised gene expression tests. OSB enables efficient local profiling of 21 genes predictive of chemotherapy benefit, eliminating overseas sample shipping. This reduces costs, accelerates turnaround times, and improves test accessibility. OSB provides healthcare systems with a decentralised solution for personalised care, helping thousands of women avoid unnecessary chemotherapy and its debilitating side effects. This grant will serve as a key catalyst for SigBio, advancing OSB from its prototype status to a fully developed, user-friendly kit.

Holly Health is an intelligent, compassionate, fully digital, health coaching service, already used by NHS organisations in over 20 regions in the UK. The product aims to address the lack of tailored coaching support and proactive prevention services available to patients for making sustainable physical and mental health changes.